The March 10, 2019, article by O’Connor et al entitled “Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma” (J Clin Oncol 10.1200/JCO.18.00899) was published with errors.
In Table 3, the number of response-evaluable patients in three of the column headers read as:
Gemcitabine (n = 30), Pralatrexate (n = 80), and Romidepsin (n = 23).
They should have read as:
Gemcitabine (n = 23), Pralatrexate (n = 51), and Romidepsin (n = 18).
This has been corrected as of January 15, 2020. The authors apologize for the errors.